At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 407 enrolled
Drug / intervention
tapinarof cream, 1% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults
In Brief
A Phase 3 clinical trial evaluating tapinarof cream, 1% and Vehicle cream for Atopic Dermatitis. Completed, enrolled 407 participants across 67 sites in 2 countries.
Detailed Summary
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartSep 2021
Primary CompletionMar 2023
Study CompletionApr 2023
TodayJul 2026
First PostedAug 20, 2021
Enrollment StartSep 1, 2021
Primary CompletionMar 30, 2023
Study CompletionApr 7, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.9 years ago
Interventions
tapinarof cream, 1%drug
applied topically once daily
Vehicle creamdrug
applied topically once daily